South Central Railway Recruitment 2021: Apply for 60 medical staff posts on scr.indianrailways.gov.in

-

The South Central Railway (SCR) has started the online application process to fill the vacancies of medical staff. Interested candidates can apply by visiting the official website scr.indianrailways.gov.in.

This recruitment drive will fill 60 posts while the registration process will close down on 27 April, the South Central Railway said in a notification.

Applicants should be aware that the number of positions may increase or decrease as per administrative needs. The details of the vacancies are as follows:

  1. Specialist doctor (one post)
  2. Contract medical practitioners (13 posts)
  3. Nursing sisters (21 posts)
  4. Pharmacist (2 posts)
  5. Hospital attendants (23 posts)

Aspirants can follow these steps:

Step 1: Visit the official website, scr.indianrailways.gov.in

Step 2: On the home page, go to the ‘recruitment’ tab and find the notification

Step 3: Read the notification before applying

Step 4: Click on the Google form link given in the notification and submit it

Step 5: Mail the scanned copies of the prescribed application and required documents to the email ids mentioned in the advertisement for the respected post

Selection process

The selection process will include interviews. Eligible candidates need to be alert as the interview date and time will be informed through personal mobile number and email ID.

Age Limit

The age limit for specialist doctor and contract medical practitioner is up to 53 years of age, whereas for nursing sisters it is between 20 to 33 years of age. The age limit for pharmacist is 20 to 33 years and candidates for hospital attendant should be between 18 to 30 years of age.

Selected candidates who will be appointed for the posts will be taken under a contract for a period of three months. The contract will last from the date of engagement or till the currency of the scheme exists (up to 30 June).



from Firstpost India Latest News https://ift.tt/3xlMyeU
FP Trending

Comments

Post a Comment

Popular posts from this blog

Both COVID-19 vaccine doses needed for good protection against B16172 variant

-
It’s been a concerning few weeks in the UK, with the B16172 variant first taking hold and then spreading to become dominant. This more infectious form of the virus, initially identified in India, is what we’re now going to have to live with – unless it is out-competed by another variant in the future. Worryingly, experts had predicted that B16172 might be able to escape some of the effects of vaccines, which if true would threaten to derail the UK’s plans to finish lifting restrictions from the end of June. However, Public Health England (PHE) has looked at the ability of various variants to evade immunity and says that the UK’s vaccines remain effective against the variants circulating, including B16172. On the surface, this looks like good news. But delve a bit deeper, and things get more complicated, says Paul Hunter, professor of medicine at the University of East Anglia. PHE’s research found a little drop-off in protection against B16172 among people who were fully vaccinated.
Read more

New coronavirus variant emerge in India: How should our COVID response change?

-
Image
After genome sequencing of over 10,000 COVID-19 cases in India, researchers have discovered a new variant with two new mutations which may be better at evading the immune system. In 15-20 percent of samples from the Indian state of Maharashtra (the state accounting for 62 percent of cases in the country) a new, double mutation in key areas of the virus has been detected. These are now known as the E484Q and L452R mutations. What makes the variant different? Both these mutations are concerning because they are located in a key portion of the virus – the spike protein – that it uses to penetrate human cells. Spike proteins attach via a “receptor binding domain”, meaning the virus can attach to receptors in our cells. These new mutations include changes to the spike protein that make it a “better fit” for human cells. This means the virus can gain entry more easily and multiply faster. Given what we have seen with other similar mutations , it might also make it harder for our immu
Read more

Aditya L1 Mission: Spacecraft is nearing its final phase, says ISRO chief

-
Aditya L1 spacecraft is nearing its final phase, and manoeuvres to enter the L1 point are expected to be completed by January 7, 2024, according to ISRO Chairman S Somanath. “Aditya is on the way. I think it has reached almost its final phase,” the ISRO chief told PTI on the sidelines of an event organised at VSSC to commemorate the 60th year of the First Sounding Rocket Launch. Aditya L1, India’s first space-based mission to study the Sun, was successfully launched on September 2 from the Satish Dhawan Space Centre (SDSC) in Sriharikota. The spacecraft, after travelling about 1.5 million km from Earth over 125 days, is expected to be placed in a Halo orbit around the Lagrangian point L1, considered closest to the Sun. He said that the last preparations for the spacecraft’s entry into the L1 point are currently underway incrementally.”Possibly by January 7th, the final manoeuvres will be done for entering into the L1 point,” Somanath added. Among other tasks, it will capture and tr
Read more